CL2017003024A1 - Tratamiento para el cancer a traves de la manipulación de microflora comensal - Google Patents

Tratamiento para el cancer a traves de la manipulación de microflora comensal

Info

Publication number
CL2017003024A1
CL2017003024A1 CL2017003024A CL2017003024A CL2017003024A1 CL 2017003024 A1 CL2017003024 A1 CL 2017003024A1 CL 2017003024 A CL2017003024 A CL 2017003024A CL 2017003024 A CL2017003024 A CL 2017003024A CL 2017003024 A1 CL2017003024 A1 CL 2017003024A1
Authority
CL
Chile
Prior art keywords
manipulation
cancer treatment
commensal microflora
commensal
microflora
Prior art date
Application number
CL2017003024A
Other languages
English (en)
Inventor
Thomas F Gajewsky
Ayelet Sivan
Leticia Corrales
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57441608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of CL2017003024A1 publication Critical patent/CL2017003024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
CL2017003024A 2015-06-01 2017-11-28 Tratamiento para el cancer a traves de la manipulación de microflora comensal CL2017003024A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169112P 2015-06-01 2015-06-01
US201562248741P 2015-10-30 2015-10-30

Publications (1)

Publication Number Publication Date
CL2017003024A1 true CL2017003024A1 (es) 2018-07-06

Family

ID=57441608

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003024A CL2017003024A1 (es) 2015-06-01 2017-11-28 Tratamiento para el cancer a traves de la manipulación de microflora comensal

Country Status (18)

Country Link
US (4) US9855302B2 (es)
EP (2) EP4541361A3 (es)
JP (2) JP2018521013A (es)
KR (2) KR20240059639A (es)
CN (1) CN107847530A (es)
AU (1) AU2016270750B2 (es)
BR (1) BR112017025813A2 (es)
CA (1) CA2987129A1 (es)
CL (1) CL2017003024A1 (es)
HK (1) HK1253064A1 (es)
IL (1) IL255940A (es)
MX (1) MX2017015473A (es)
PE (1) PE20180673A1 (es)
RU (1) RU2017141448A (es)
TW (1) TW201717975A (es)
UY (1) UY36701A (es)
WO (1) WO2016196605A1 (es)
ZA (2) ZA201707986B (es)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094027A1 (en) 2010-02-01 2011-08-04 Hlavka Edwin J Bacteriotherapy for clostridium difficile colitis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
PL3065748T3 (pl) 2014-12-23 2018-07-31 4D Pharma Research Limited Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
KR20200091499A (ko) 2015-05-06 2020-07-30 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MD3650033T2 (ro) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compoziții conţinând tulpini bacteriene
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3240554T1 (sl) 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3554521A4 (en) 2016-12-15 2020-09-16 The Regents of The University of California ORAL COMPOSITION CONTAINING LACTIC ACID BACTERIA TO REGULATE IMMUNE REACTIONS AND RELATED METHODS
EP3559257A1 (en) * 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
IL296740B2 (en) * 2016-12-23 2023-09-01 Univ Keio Compositions and methods for the induction of cd8+ t-cells
US11666646B2 (en) 2016-12-26 2023-06-06 National University Corporation Kobe University Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
EP3570856A2 (en) * 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
WO2018145082A1 (en) * 2017-02-06 2018-08-09 New York University Methods and compositions for treating and diagnosing pancreatic cancers
WO2018171555A1 (en) * 2017-03-20 2018-09-27 Crown Bioscience Inc. (Taicang) Use of gut microbiota composition in immunotherapy
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
EP3634443B1 (en) 2017-06-05 2024-09-18 The University of Chicago Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
MD3804737T2 (ro) 2017-06-14 2022-10-31 4D Pharma Res Limited Compoziții care conțin tulpini bacteriene
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
CN115813955A (zh) 2017-06-14 2023-03-21 4D制药研究有限公司 包含细菌菌株的组合物
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
US20190175560A1 (en) * 2017-12-01 2019-06-13 Shepherd Therapeutics, Inc. Mebendazole cancer therapies and methods of use
ES2972746T3 (es) * 2018-01-17 2024-06-14 Reponex Pharmaceuticals As Composiciones para eliminar promotores bacterianos del cáncer colorrectal mediante aplicación intraluminal
CN111902153A (zh) * 2018-01-19 2020-11-06 4D制药研究有限公司 用于治疗或预防癌症的组合疗法
AU2019210003A1 (en) * 2018-01-19 2020-07-30 4D Pharma Research Limited Combination therapy for treating or preventing cancer
CA3088338A1 (en) * 2018-01-19 2019-07-25 4D Pharma Research Limited Combination therapy for treating or preventing cancer
AU2019210002A1 (en) * 2018-01-19 2020-08-13 4D Pharma Research Limited Combination therapy for treating or preventing cancer
CN110090230B (zh) * 2018-01-30 2022-07-12 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用
WO2019149859A1 (en) * 2018-01-31 2019-08-08 Universität Basel Gut commensal bacteria for treatment of human colorectal cancer
WO2019156234A1 (en) * 2018-02-09 2019-08-15 Keio University Compositions and methods for the induction of cd8+ t-cells
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP2021519299A (ja) * 2018-03-28 2021-08-10 セレス セラピューティクス インコーポレイテッド 微生物叢モジュレーションによる癌の治療
KR101980525B1 (ko) * 2018-04-12 2019-05-21 주식회사 지놈앤컴퍼니 락토코커스 락티스 gen3013 균주, 및 이를 포함하는 암의 예방 또는 치료용 조성물
WO2019232284A1 (en) * 2018-05-30 2019-12-05 Evolve Biosystems, Inc. Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis
US11759485B2 (en) 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
EP4467131A3 (en) * 2018-07-17 2025-01-22 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
CA3106429A1 (en) * 2018-08-05 2020-02-13 Da Volterra Method for improving anticancer agent efficacy
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
CN112805020B (zh) * 2018-09-25 2025-03-25 国立研究开发法人国立循环器病研究中心 抗肿瘤效果增强剂
CN109266766B (zh) * 2018-10-10 2021-10-19 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CA3120709A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2020122476A1 (ko) * 2018-12-10 2020-06-18 한국식품연구원 락토바실러스 사케아이 wikim30을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102136772B1 (ko) * 2018-12-10 2020-07-23 한국식품연구원 락토바실러스 사케아이 wikim30을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
CN110106104B (zh) * 2019-03-19 2021-12-17 江南大学 假小链双歧杆菌ccfm1048、其组合物、发酵食品、用途、菌剂及其菌剂制备方法
IL265735A (en) 2019-03-31 2019-05-30 Biomica A microbial consortium and its uses
CN111773377B (zh) * 2019-04-04 2023-03-14 中南大学 阿尼芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110063970B (zh) * 2019-04-30 2024-09-03 上海心脉途医疗科技有限公司 与irAE相关的肠道菌群及irAE的治疗和预防方法
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
CN110734888B (zh) * 2019-09-17 2021-08-03 广州维生君生物科技有限公司 Tim3人源单链抗体融合基因转化乳酸菌及其应用
AU2020373179A1 (en) * 2019-11-01 2022-05-19 Uti Limited Partnership Harnessing the power of microbiota and metabolites for the treatment of cancer
WO2021127235A1 (en) 2019-12-20 2021-06-24 Persephone Biosciences, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
WO2021146647A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating cancer
CN111228315A (zh) * 2020-02-27 2020-06-05 上海上药信谊药厂有限公司 抗肿瘤组合物
CN111096982B (zh) * 2020-02-27 2023-09-12 上海上药信谊药厂有限公司 抗肿瘤组合物
US20220120746A1 (en) * 2020-03-18 2022-04-21 Sabine Hazan Methods of Determining Susceptibility to COVID-19 Infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
NL2025863B1 (en) 2020-06-19 2022-02-17 Acad Medisch Ct Fecal matter for treatment of cachexia
KR102351601B1 (ko) 2020-07-06 2022-01-13 연세대학교 산학협력단 장내 미생물 기반 면역 항암 요법의 치료 반응 예측과 향상 방법 및 후보 프리바이오틱스 스크리닝 방법
JP2023539640A (ja) 2020-08-28 2023-09-15 株式会社 リビオム 抗腫瘍細菌株、並びにそれを利用した組成物及びその方法
KR20220028425A (ko) 2020-08-28 2022-03-08 주식회사 리비옴 항종양 세균 균주, 및 이를 이용한 조성물 및 방법
KR102489493B1 (ko) * 2020-08-31 2023-01-18 주식회사 리비옴 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법
JP2023550544A (ja) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
KR102307603B1 (ko) * 2020-11-13 2021-10-05 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
US20240277778A1 (en) * 2021-06-09 2024-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for determining responsiveness to immune checkpoint inhibitors (ici), increasing effectiveness of ici, and treating cancer
JP2024534805A (ja) * 2021-08-17 2024-09-26 フォンダツィオーネ ペル リスティトゥート オンコロジコ ディ リチェルカ （イオエッレ） 共生細菌は前立腺がんにおいてアンドロゲン生合成を介して内分泌抵抗性を促進する
CN115786156A (zh) * 2021-09-10 2023-03-14 香港中文大学 用于结直肠肿瘤的预防、治疗或风险控制的组合物
WO2023118868A1 (en) * 2021-12-21 2023-06-29 Quadram Institute Bioscience Bifidobacterium and compositions thereof for breast cancer treatment
CN114344342B (zh) * 2021-12-29 2023-06-30 广东南芯医疗科技有限公司 副干酪乳杆菌Lp. R3在制备预防或治疗肿瘤药物中的应用
WO2023141119A1 (en) * 2022-01-18 2023-07-27 The Regents Of The University Of California Bacterial compositions and methods for treating cancer and immune diseases
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024035638A1 (en) * 2022-08-08 2024-02-15 Cornell University Methods for classifying and treating gastrointestinal tumors based on mycobiome analysis
IT202200022401A1 (it) * 2022-10-31 2024-05-01 Probionova Sa Ceppi di batteri per il trattamento di disturbi urologici, loro composizioni e usi relativi
CN117089490B (zh) * 2023-08-11 2024-06-07 浙江大学 青春双歧杆菌basj001及应用
WO2025176152A1 (en) * 2024-02-19 2025-08-28 The University Of Hong Kong Probiotics mixtures and methods of use thereof for treating cancers
CN118001305B (zh) * 2024-04-09 2024-06-11 山东中科嘉亿生物工程有限公司 长双歧杆菌jblc-141在制备改善副肿瘤性血小板增多症药物中的应用
WO2026011048A1 (en) * 2024-07-03 2026-01-08 Ohio State Innovation Foundation Commensal bacterial antigen as a therapeutic agent for cancers
CN121550264B (zh) * 2026-01-26 2026-04-17 华中科技大学同济医学院附属协和医院 一种基于呼吸道共生菌的抗肿瘤制剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP2005089388A (ja) * 2003-09-18 2005-04-07 Biofuerumin Seiyaku Kk 免疫賦活作用増強剤
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US8444967B2 (en) 2010-07-09 2013-05-21 Master Supplements, Inc. Treatment including prebiotic composition for use with probiotics
DE102008045815A1 (de) * 2008-09-05 2010-03-11 Universität Rostock Kombination aus mindestens einem Antikörper und einem Bakterium, welches Fc-Rezeptoren oder die leichte Kette eines Antikörpers bindendende Proteine exprimiert
RU2546251C2 (ru) * 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
HK1220326A1 (zh) 2013-03-15 2017-05-05 Seres Therapeutics, Inc. 基於网络微生物组成和方法
CN104415060A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
CA2965114A1 (en) * 2013-10-21 2015-04-30 Hemoshear, Llc In vitro model for a tumor microenvironment
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
RU2695332C2 (ru) * 2014-05-15 2019-07-23 Бристол-Маерс Сквибб Компани Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
AU2015334468B2 (en) 2014-10-23 2021-06-17 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
TW201906620A (zh) * 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法

Also Published As

Publication number Publication date
KR20240059639A (ko) 2024-05-07
ZA201707986B (en) 2020-01-29
US20220296656A1 (en) 2022-09-22
KR102661603B1 (ko) 2024-04-29
HK1253064A1 (zh) 2019-06-06
RU2017141448A (ru) 2019-07-15
JP2022000447A (ja) 2022-01-04
EP3303401A1 (en) 2018-04-11
EP4541361A2 (en) 2025-04-23
CA2987129A1 (en) 2016-12-08
KR20180011262A (ko) 2018-01-31
EP3303401A4 (en) 2018-12-26
US9855302B2 (en) 2018-01-02
ZA201907641B (en) 2021-05-26
AU2016270750A1 (en) 2017-12-14
AU2016270750B2 (en) 2022-06-16
MX2017015473A (es) 2018-08-15
UY36701A (es) 2016-12-30
US20190183942A1 (en) 2019-06-20
CN107847530A (zh) 2018-03-27
WO2016196605A1 (en) 2016-12-08
EP3303401B1 (en) 2024-10-16
RU2017141448A3 (es) 2019-11-19
PE20180673A1 (es) 2018-04-19
IL255940A (en) 2018-01-31
TW201717975A (zh) 2017-06-01
EP3303401C0 (en) 2024-10-16
US20160354416A1 (en) 2016-12-08
JP2018521013A (ja) 2018-08-02
US20180015131A1 (en) 2018-01-18
BR112017025813A2 (pt) 2018-08-14
EP4541361A3 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
ZA201907641B (en) Treatment of cancer by manipulation of commensal microflora
IL255261A0 (en) Methods for treating cancer
IL255217A0 (en) Cancer neoepitopes
EP3463464A4 (en) ASSOCIATION TREATMENT
PT3283527T (pt) Terapêutica de combinação para o cancro
PT3377516T (pt) Composição para o tratamento do cancro
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
PL3265053T3 (pl) Sposoby leczenia skóry
PL3423087T3 (pl) Skojarzona terapia przeciwnowotworowa
PL3197456T3 (pl) Leczenie nowotworów
PT3572410T (pt) Análogos dioxolano de uridina para o tratamento de cancro
IL252630B (en) Lanthionine synthetase c-like 2-based therapeutics
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3413927A4 (en) CANCER THERAPY
IL260347A (en) Therapeutic anti-cd9 antibody
CL2016001666S1 (es) Cerradura para maleta
EP3593139C0 (en) CANCER BIOMARKERS
FI20155670A7 (fi) Lukkorunko
DK3576740T3 (da) Cancerbehandling
DK3408265T3 (da) Terapeutiske forbindelser
PL3134119T3 (pl) Leczenie nowotworu
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL262851A (en) Combination prime: boost therapy